Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma

Autor: Judith Rosen Farrar, Joseph A. Smith, Gary Feiss, MJ Welch, Sharon Levy
Rok vydání: 1997
Předmět:
Pulmonary and Respiratory Medicine
Adult
Male
Triamcinolone acetonide
Time Factors
Adolescent
medicine.drug_class
medicine.medical_treatment
Anti-Inflammatory Agents
Peak Expiratory Flow Rate
Critical Care and Intensive Care Medicine
Triamcinolone Acetonide
Drug Administration Schedule
Pulmonary function testing
Placebos
Double-Blind Method
Forced Expiratory Volume
Administration
Inhalation
medicine
Humans
Albuterol
Glucocorticoids
Asthma
Aerosols
Chemotherapy
Inhalation
Dose-Response Relationship
Drug
business.industry
Incidence
Respiratory disease
Pharyngitis
Adrenergic beta-Agonists
Middle Aged
medicine.disease
Dose-ranging study
respiratory tract diseases
Bronchodilator Agents
Evaluation Studies as Topic
Anesthesia
Chronic Disease
Linear Models
Corticosteroid
Female
Cardiology and Cardiovascular Medicine
business
medicine.drug
Zdroj: Chest. 112(3)
ISSN: 0012-3692
Popis: This multicenter, double-blind, placebo-controlled study evaluated the dose response to 6 weeks of triamcinolone acetonide inhalation aerosol (TAA, 100 microg per puff) in patients with moderately severe asthma.A total of 285 patients were randomly assigned to treatment with 1, 2, 4, or 8 puffs TAA (total daily doses of 200, 400, 800, and 1,600 microg, respectively), administered twice daily, or matching placebos. Efficacy was assessed by changes in FEV1, asthma symptom scores, albuterol use, and peak flow rates.Linear trend analyses showed a dose response for all efficacy variables across the dose range of 200 to 1,600 microg daily. Therapeutic activity was evident at a dose of 200 microg daily for all variables, with significant clinical efficacy (p0.05) demonstrated for all doses except for reduction in inhaled albuterol use which achieved statistical significance at 400 microg/d. Daily doses of 400 microg and higher showed response plateaus at 3 weeks of treatment that were maintained for the remainder of the trial. The incidence of adverse events was similar in all treatment groups, although more patients treated with TAA reported pharyngitis in a dose-related manner.Our findings suggest that most patients with chronic, moderately severe asthma can be treated adequately with doses of TAA between 200 microg (1 puff bid) and 800 microg (4 puffs bid) daily. At this dose range, clinically significant improvements are evident in symptoms, pulmonary function, and rescue medication use.
Databáze: OpenAIRE
Externí odkaz: